Article ID Journal Published Year Pages File Type
6114456 Autoimmunity Reviews 2015 8 Pages PDF
Abstract
The treatment of patients with CSS must be tailored to individual patients according to the presence of poor prognostic factors. A combination of high-dose corticosteroids and cyclophosphamide is still the gold standard for the treatment of severe cases, but the use of biological agents such as rituximab or mepolizumab seems to be a promising therapeutic alternative.
Related Topics
Life Sciences Immunology and Microbiology Immunology
Authors
, , , , , , , ,